

1
2
3
4 **Clinical presentation and outcome of pediatric ANCA-associated**
5
6 **glomerulonephritis**
7

8
9 Anne M. Kouri and Sharon P. Andreoli
10

11
12
13
14
15 Indiana University School of Medicine
16

17
18 Department of Pediatric Nephrology
19

20
21 699 Riley Hospital Drive, Rm 230
22

23
24 Indianapolis, IN 46202
25
26
27
28
29

30 Corresponding author:
31

32
33 Anne M. Kouri, MD
34

35
36 akouri@iupui.edu
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56

57
58 This is the author's manuscript of the article published in final edited form as:
59

60
61 Kouri, A. M., & Andreoli, S. P. (2017). Clinical presentation and outcome of pediatric ANCA-associated
62 glomerulonephritis. *Pediatric Nephrology*, 32(3), 449–455. <https://doi.org/10.1007/s00467-016-3490-6>
63
64
65

1
2
3
4 **ABSTRACT**
5
6

7 *Introduction:* Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a
8 small- and medium-sized vasculitis classically seen in adult patients with peak onset
9 near the fifth to seventh decade of life. There is little data on ANCA-associated
10 vasculitis in pediatric patients and most studies have limited follow-up.
11
12
13
14
15

16
17 *Methods:* This is a retrospective chart review of 22 patients in a single institution from
18 1991 to 2013.
19
20
21

22
23 *Results:* Of the 22 patients in our institution with ANCA-positive glomerulonephritis,
24 eight patients (36 %) required renal replacement therapy (RRT) at diagnosis; four of
25 these patients recovered sufficient renal function to initially discontinue dialysis. Five
26 patients (23 %) were treated with plasmapheresis at presentation. The median time
27 from presentation until first clinical or serologic relapse was 1.7 ± 1.2 years. After a
28 median follow-up of 5.8 years, just over half of our patients have chronic kidney disease
29 (CKD) stages 1-3 (55 %). Seven (32 %) patients progressed to end-stage renal disease
30 (ESRD) and eventually required kidney transplant.
31
32
33
34
35
36
37
38
39
40
41

42 *Conclusion:* ANCA-associated glomerulonephritis is a rare disorder in children.
43 Presentation and outcomes vary significantly amongst patients. More research is
44 required to follow these patients who are diagnosed in childhood to further characterize
45 the long term outcome of the disease.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61

1
2
3
4 **KEYWORDS:**
5

6
7 ANCA-positive glomerulonephritis; Rapidly-progressive glomerulonephritis; Pediatric
8 glomerulonephritis; Granulomatosis with polyangiitis; Microscopic polyangiitis; Children
9
10

11
12
13
14
15 **ABBREVIATIONS:**
16

17
18 AAV: ANCA-associated vasculitis
19

20
21 ANCA: Anti-neutrophil cytoplasmic antibody
22

23
24 AGN: ANCA-associated glomerulonephritis classification
25

26
27 c-ANCA: cytoplasmic anti-neutrophil cytoplasmic antibody
28

29
30 CKD: Chronic kidney disease
31

32
33 ESRD: End stage renal disease
34

35
36 EPA: Eosinophilic granulomatosis with polyangiitis
37

38
39 GFR: Glomerular filtration rate
40

41
42 GPA: Granulomatosis with polyangiitis
43

44
45 MPA: Microscopic polyangiitis
46

47
48 MPO: Myeloperoxidase
49

50
51 PR3: Proteinase 3
52

53
54 p-ANCA: perinuclear anti-neutrophil cytoplasmic antibody
55

56
57 RPGN: Rapidly progressing glomerulonephritis
58

59
60 RRT: Renal replacement therapy
61

1
2
3
4 **INTRODUCTION**
5
6

7 Dr. J. Charles Jennette and Dr. Ronald J. Falk first characterized the association
8 of anti-neutrophil cytoplasmic antibodies (ANCA) with necrotizing vasculitis in the 1980s
9 and 1990s [1]. ANCA-associated vasculitis (AAV) is a small- and medium-sized
10 vasculitis which has since been classified in to three separate entities: granulomatosis
11 with polyangiitis (GPA, formerly Wegener’s granulomatosis), microscopic polyangiitis
12 (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA) [2]. It is a disease
13 classically seen in adults and is rare in the pediatric population. The peak age of onset
14 is commonly between the fifth and seventh decade of life [3]. As a result, much of the
15 data and treatment protocols are extrapolated from adult data and applied to pediatric
16 patients.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

32 The data on ANCA-associated renal disease in children is mostly in the form of
33 case series and retrospective studies with limited follow-up. Similar to other childhood
34 chronic diseases, children with AAV differ from adults in that they have a longer
35 anticipated life span over which their disease must be managed. The peak age of onset
36 of AAV in the pediatric population is during late childhood and adolescence, a critical
37 time for growth as well as emotional, physical and reproductive development [4-6].
38 Critical therapeutic decisions must be made to maximize quality of life as well as long-
39 term renal and overall survival. Thus, longitudinal data in this patient population is
40 needed to see the potential evolution of disease through childhood, adolescence and
41 into adulthood.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 The purpose of this study is to describe pediatric ANCA-associated
5
6 glomerulonephritis at a single center and to compare our experience with previously
7
8 published adult and pediatric literature.
9

10 11 12 13 14 15 **METHODS**

16
17
18 This study was approved by the Institutional Review Board (IRB) governing
19
20 Indiana University School of Medicine. It is a retrospective chart review of 22 patients
21
22 with ANCA-positive glomerulonephritis diagnosed or managed from 1991 to 2013 within
23
24 the Pediatric Nephrology and Hypertension Division at Riley Hospital for Children at
25
26 Indiana University Health, a tertiary care center with a pediatric nephrology division in
27
28 addition to other pediatric subspecialties. The IRB granted a waiver of consent for this
29
30 study. We identified patients from the GE-Centricity Business (IDX) billing system based
31
32 on ICD-9 codes available to our institution for billing. The following codes generated a
33
34 list of 213 patients: 446.0 polyarteritis nodosa and allied conditions, 580.4 acute
35
36 glomerulonephritis, 582.0 chronic glomerulonephritis, 584.5 acute kidney failure with
37
38 tubular necrosis, and 584.9 acute kidney failure. From this list, 23 patients were
39
40 identified as ANCA-positive. One patient was ANCA-positive but upon further review
41
42 had questionable renal involvement and was excluded. In total, 22 patients with ANCA-
43
44 positive disease and active renal involvement were included in the study.
45
46
47
48
49
50
51

52
53 Patients were selected if they met the following criteria: (1) ANCA-positive
54
55 serology with clinical renal involvement and/or (2) biopsy findings consistent with the
56
57 diagnosis of ANCA-positive glomerulonephritis. Charts were reviewed for demographic
58
59 information as well as clinical and laboratory characteristics at presentation, relapse and
60
61

1
2
3
4 most recent follow-up. The patients were considered to have suffered a serologic
5
6 relapse if their ANCA titer started to rise after a previous period of stability or became
7
8 positive after having been negative. Patients were considered to have had a clinical
9
10 relapse if they developed symptoms that required changes in medical therapy. The
11
12 estimated glomerular filtration rate for each patient was calculated using the modified
13
14 Schwartz equation [7]. Length of follow-up was determined from the time of presentation
15
16
17 to the time of transplant or to the time of most recent follow-up for those patients who
18
19 did not progress to end-stage renal disease (ESRD) or to the date of most recent
20
21 available clinical information. All patients who progressed to ESRD were transplanted.
22
23
24
25
26
27
28

29 *Statistics*

30
31
32 Statistical analysis was performed using IBM SPSS 23® statistical software.
33
34
35 Continuous variables were compared using the Mann-Whitney-U test.
36
37
38
39
40

41 **RESULTS**

42 *Demographic information*

43
44
45
46
47 A total of 1017 unique patients were diagnosed with glomerulonephritis from
48
49 1991 to 2013 at our institution; 22 patients were identified as having ANCA-positive
50
51 glomerulonephritis, making the proportion of patients with ANCA-associated
52
53 glomerulonephritis 2.16 %. Of the 22 patients in our institution with ANCA-positive
54
55 glomerulonephritis, 13 patients (59 %) were female. The median age at presentation
56
57 was 13.7 years (IQR 11.6—15.7). Males presented at an older age than females, but
58
59
60
61
62
63
64
65

1
2
3
4 this was not statistically significant ($p=0.08$). See Table 1 for a summary of patient
5 demographics and presenting characteristics.
6
7
8
9

10 11 12 *Clinical presentation and initial treatment* 13

14
15 Twenty of 22 patients had documented systemic symptoms reported at
16 presentation. Diagnosis and initial management took place at outside institutions for two
17 patients. Figure 1 characterizes the percentage of patients with the most common
18 presenting symptoms. The most commonly reported symptoms were respiratory in
19 nature, with 55 % of patients having documented pulmonary or sinus involvement.
20 Other patients presented with non-specific complaints of body aches, malaise and
21 fatigue. One patient presented with heart failure requiring inotropic support.
22
23
24
25
26
27
28
29
30
31

32
33 The renal involvement at presentation varied considerably, details of which are
34 shown in Table 1. All of our patients presented with hematuria, proteinuria or both.
35 Renal biopsy was performed on 21 patients, 19 of which were performed at our
36 institution. One patient did not have a biopsy performed due to the critical nature of the
37 patient's condition at presentation. We classified the renal biopsies into the most
38 appropriate histopathologic categories: focal, crescentic, mixed, and sclerotic according
39 to the ANCA-associated glomerulonephritis (AGN) classification [8-10].
40
41
42
43
44
45
46
47
48
49

50
51 Of the twenty patients initially diagnosed and managed at our hospital, all were
52 treated with varying regimens at presentation. Every patient received a
53 methylprednisolone pulse (500 mg to 2000 mg per dose), varying between 2 and 6
54 doses over 2 to 12 days. Following administration of pulse-dose steroids, each of the
55
56
57
58
59
60
61

1
2
3
4 patients was transitioned to oral prednisone at 2 mg/kg/day up to a maximum dose of
5
6 60 mg/day. With the exception of four patients, all patients were treated with either oral
7
8 or IV cyclophosphamide. Maintenance immunosuppression for each individual patient
9
10 was left to the discretion of the treating physician and therefore no standard protocol
11
12 was used. However, maintenance therapy often consisted of a combination of
13
14 prednisone with another agent including mycophenolate mofetil, azathioprine, or
15
16 hydroxychloroquine. One patient was treated with twice weekly etanercept injections.
17
18
19
20
21

22 Eight patients (36 %) required renal replacement therapy (RRT) at the time of
23
24 initial presentation; four of these patients recovered sufficient renal function to
25
26 discontinue dialysis. Five patients (23 %) were treated with plasmapheresis at
27
28 presentation. The decision to perform plasmapheresis was at the discretion of the
29
30 attending nephrologist and generally was reserved for those with the most severe
31
32 disease at presentation or those who had a slow response to initial therapy. One patient
33
34 who required plasmapheresis did not require concurrent RRT; three years following
35
36 diagnosis, this patient remains off RRT with CKD stage 3. Of the remaining four patients
37
38 who required RRT and were treated with plasmapheresis, two patients recovered renal
39
40 function. One was able to discontinue continuous veno-venous hemofiltration after 25
41
42 days. The other patient's dialysis duration was unavailable. They were both able to
43
44 remain off dialysis at most recent follow-up with CKD Stage 2 at 3 and 6 years following
45
46 diagnosis.
47
48
49
50
51
52
53
54
55
56

57 *Failure of induction therapy and relapse*
58
59
60
61
62
63
64
65

1
2
3
4 Following induction therapy, two of our patients (9 %) did not successfully enter
5 remission. One patient was treated with methylprednisolone pulses as well as weekly
6 methotrexate, intravenous cyclophosphamide in addition to hydroxychloroquine but
7 ultimately died in the acute phase of the illness. In the days leading to up to death, the
8 cyclophosphamide and methotrexate were discontinued due to persistent neutropenia.
9 The patient eventually succumbed to complications of pulmonary fibrosis. The other
10 patient who failed induction therapy was treated with methylprednisolone, intravenous
11 cyclophosphamide, azathioprine, mycophenolate mofetil and required dialysis and
12 eventually kidney transplantation.
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 Twelve patients (55 %) experienced at least one serologic or clinical relapse. Of
28 these patients, 9 suffered from solely serologic relapses, 2 experienced serologic
29 relapses associated with clinical symptoms, and 1 patient had a documented clinical
30 relapse without evidence of serologic relapse. The median length of time from
31 presentation until first clinical or serologic relapse was 1.7 years (IQR 1.0—2.2). Figure
32 2 is a Kaplan-Meier curve illustrating the relapse-free survival for all 22 patients. At least
33 8 patients (67 %) suffered their first relapse while on immunosuppressive medication. Of
34 these 8 patients, 3 patients relapsed while on mycophenolate mofetil in combination
35 with prednisone, 1 on azathioprine in combination with every-other-day prednisone (40
36 mg), 1 on cyclophosphamide in combination with daily prednisone (5 mg), and 3
37 relapsed while on every-other-day prednisone (50 mg, 30 mg, 5 mg). Seven patients
38 (32 %) experienced more than one relapse.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

56 All 3 patients with a confirmed clinical component to his or her first relapse were
57 treated with increases in immunosuppression, including increases in prednisone and
58
59
60
61
62
63
64
65

1
2
3
4 mycophenolate mofetil, and in the case of 1 patient, with the initiation of high-dose
5
6 methylprednisolone and cyclophosphamide. Despite aggressive treatment, two of these
7
8 patients progressed to ESRD.
9

10
11 Not all serologic relapses were treated with increases in immunosuppressive
12
13 therapy. Four patients with first-time serologic relapses were documented to have had
14
15 increases in immunosuppression prescribed by their provider. There was no
16
17 standardized treatment protocol for treatment of clinical or serologic relapse, so it is
18
19 difficult to draw conclusions regarding treatment efficacy based on our data.
20
21
22
23
24
25
26

27 ESRD and transplant

28
29
30 The median length of time to follow-up for all patients was 5.8 years (IQR 3.0-
31
32 8.3). Two patients were lost to follow-up. Seven (32 %) patients progressed to ESRD
33
34 and required kidney transplant. Median estimated glomerular filtration rate at most
35
36 recent follow-up of those patients who did not progress to ESRD was 61.1
37
38 mL/min/1.73m² (IQR 49.3—78.0). The median time from presentation to kidney
39
40 transplant was 3.5 years (IQR 2.0—8.3).
41
42
43
44

45
46 Table 2 illustrates the renal outcomes for our patients. Of the eight patients that
47
48 required dialysis at presentation, five patients (63 %) progressed to require kidney
49
50 transplantation. The median creatinine at presentation for those patients who did
51
52 eventually progress to ESRD was 8.85 mg/dL (IQR 2.4—28.9). The creatinine of those
53
54 patients who did not progress to ESRD overall trended lower at presentation with a
55
56
57
58
59
60
61

1
2
3
4 median of 2.2 mg/dL (IQR 0.9—5.6). However, this difference was not statistically
5
6 significant.
7
8

9
10 Two patients who progressed to ESRD did not present with a need for dialysis.
11 For those 2 patients, the serum creatinine at presentation was 1.5 mg/dL and 2.7 mg/dL
12
13 at ages 17.4 years and 11.1 years, respectively; one patient was PR3-positive at
14
15 presentation while the other patient was actually ANCA negative at presentation and
16
17 later seroconverted to MPO-positive disease. One of these patients actually failed
18
19 induction therapy, and the other patient had frequently-relapsing disease with
20
21 subsequent decline in renal function. No patients in our study have had the rare, but
22
23 reported, complication of recurrence of disease in the transplanted kidney.
24
25
26
27
28
29
30
31

32 **DISCUSSION**

33
34
35 This is one of the largest studies to describe ANCA-positive glomerular disease
36
37 in children with one of the longest follow-up durations to date. To our knowledge, there
38
39 are only a handful of recent retrospective studies that describe clinical characteristics of
40
41 children with this disease; data are sparse in terms of long-term follow-up and
42
43 progression to ESRD. Table 3 is a summary of previously published data on pediatric
44
45 AAV with or without renal involvement. In addition, we determined that ANCA-positive
46
47 glomerulonephritis accounted for 2.16 % of cases of glomerulonephritis at our center,
48
49 documenting that ANCA-positive glomerulonephritis is rare in pediatric patients.
50
51
52
53
54

55
56 Our patient demographics are consistent with what has been previously reported
57
58 in the pediatric literature, with peak age of onset during adolescence and a female-
59
60

1
2
3
4 predominant patient population [5, 11-14]. In the adult literature, it is reported that renal
5
6 involvement in AAV can be so severe as to require dialysis-dependence in 23-60 % of
7
8 these patients [15, 16]. Our study found that 36 % of patients required dialysis at
9
10 diagnosis, which is within the range previously reported in the pediatric literature as well
11
12 [5, 6, 10-13, 17-21]. However, it is important to note that our study is based solely on
13
14 those patients with renal involvement and does not include patients without renal
15
16 involvement. This can be misleading when comparing our study to others, as 100 % of
17
18 our patients suffered from renal involvement and therefore represent the population who
19
20 is at the highest risk for dialysis.
21
22
23
24
25
26

27 Even with effective therapies, AAV is a chronic illness. In adults, AAV has been
28
29 reported to have a 90 % two-year mortality if left untreated. Modern treatment protocols
30
31 with high dose steroids, cyclophosphamide, rituximab and plasmapheresis have
32
33 improved the prognosis of this disease, but all are also associated with significant
34
35 morbidities. Also in adult populations, it is documented that induction therapy fails to
36
37 induce remission in approximately 10 % of patients [3]. Moreover, after induction
38
39 therapy and remission, many patients suffer from clinical or serologic relapse, and
40
41 kidney function has been reported to be inversely associated with relapse rate [22].
42
43
44
45
46

47 Our study's pediatric data is strikingly similar to the adult data with respect to
48
49 induction therapy and relapsing disease. Ten percent of patients in our study failed to
50
51 respond to initial therapy and over half (55 %) of patients suffered from clinical or
52
53 serologic relapse. Our data also suggest that patients who fail to enter remission with
54
55 induction therapy and those who have more frequent relapses have a worse renal
56
57 outcome. However, our study is biased by the assumption that the time of renal
58
59
60
61
62
63
64
65

1
2
3
4 involvement was simultaneous with the time of disease onset. This is not always the
5
6 case for all patients with AAV, as pediatric patients are especially vulnerable to a delay
7
8 in diagnosis, given the rarity of the disease and variability in presenting signs and
9
10 symptoms [14, 23]. In addition, the relapse rate in our study is rather high (55 %). This
11
12 may be a function of the follow-up time of the study, with ANCA titers known to fluctuate
13
14 in individual patients without evidence of clinical disease. Current guidelines do not
15
16 consider solely a change in ANCA titer a relapse, but rather a time for close clinical and
17
18 laboratory monitoring in an individual patient.
19
20
21
22
23

24 With regards to overall prognosis, the adult literature reports that older age,
25
26 female gender, higher serum creatinine and chronic histologic lesions are predictors for
27
28 worse renal outcome and overall survival [16]. Fourteen to 18 percent of adult patients
29
30 with AAV require permanent dialysis and the disease has a 23-40 % mortality rate by 1
31
32 and 5 years from diagnosis [16, 24]. In our pediatric cohort, the data also suggests that
33
34 a higher creatinine at presentation is a negative prognostic factor in terms of renal
35
36 prognosis, although our results were not statistically significant likely due to the sample
37
38 size. However, the overall renal prognosis and survival is arguably better than that of
39
40 the adult population despite the fact that seven of our patients (32 %) progressed to
41
42 ESRD and required a kidney transplant. Just over half of our patients have CKD stages
43
44 1-3 (55 %) with the median estimated glomerular filtration rate of 61.1 ml/min/1.73m² for
45
46 those patients who did not progress to ESRD at a median of 5.8 years following
47
48 diagnosis. The mortality rate in our study was much lower (1 patient, 5 %) than what
49
50 has been reported in the adult literature. Additionally, nearly two-thirds of our sample
51
52 had relatively indolent courses and had no need for RRT.
53
54
55
56
57
58
59
60
61

1
2
3
4 This study is a retrospective chart review. As for all studies with this design, there
5
6 are significant biases and limitations. These limitations should not be undermined. For
7
8 example, documented rises in ANCA titers may have been associated with more clinical
9
10 symptoms which were not clearly documented in the paper or electronic medical record,
11
12 limiting our ability to truly document a clinical versus a serologic relapse in these
13
14 patients. In addition, two patients were diagnosed at outside institutions and therefore
15
16 the information surrounding their presentation is limited. Additionally, a statistic
17
18 illustrating the duration from presentation to ESRD in the patients who developed ESRD
19
20 would have been helpful. However, the data collection was limited by what was
21
22 available in the chart and the timing of dialysis initiation was not available for most
23
24 patients.
25
26
27
28
29
30

31
32 The sample size of our study is a relative limitation. This disease is uncommon
33
34 and although we are a fairly high-volume center, approximately 1 patient with this
35
36 disease presents per year at our institution. Nonetheless, our study has a relatively
37
38 large cohort with a relatively long follow-up duration when compared to other published
39
40 pediatric literature on the topic. As such, pediatric patients, in contrast to adults, have
41
42 potentially multiple decades to live with this disease; understanding this disease over
43
44 long periods of time is essential for improvement in the care of these patients.
45
46
47
48
49
50

51 52 **CONCLUSION**

53
54
55 ANCA-positive glomerulonephritis is a rare disorder in children. At presentation,
56
57 the degree of renal involvement is quite variable, ranging from mild to very severe renal
58
59 injury. However, nearly two-thirds of our cohort were without need for RRT at a median
60
61

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

follow-up time of 5.8 years, indicating that with modern therapies this disease can be indolent despite the risk of relapse. Nonetheless, more prospective research is required to understand the disease progression in children.

Conflict of interest: The authors have no conflicts of interest to disclose.

Ethics: This study was approved by the Institutional Review Board governing Indiana University School of Medicine. A waiver of consent was granted for this study.

1
2
3
4 **REFERENCES**
5
6

- 7 1. Jennette JC, Falk RJ (1990) Antineutrophil cytoplasmic autoantibodies and
8 associated diseases: a review. *Am J Kidney Dis* 6:517-529
9
10
11
12 2. Kallenberg CG, Stegeman CA, Abdulahad WH, Heeringa P (2013) Pathogenesis of
13 ANCA-associated vasculitis: new possibilities for intervention. *Am J Kidney Dis* 6:1176-
14 1187
15
16
17
18
19
20 3. Kamesh L, Harper L, Savage CO (2002) ANCA-positive vasculitis. *J Am Soc Nephrol*
21 7:1953-1960
22
23
24
25 4. Bohm M, Gonzalez Fernandez MI, Ozen S, Pistorio A, Dolezalova P, Brogan P,
26 Barbano G, Sengler C, Klein-Gitelman M, Quartier P, Fasth A, Herlin T, Terreri MT,
27 Nielsen S, van Rossum MA, Avcin T, Castell ER, Foeldvari I, Foell D, Kondi A, Kone-
28 Paut I, Kuester RM, Michels H, Wulffraat N, Amer HB, Malattia C, Martini A, Ruperto N
29 (2014) Clinical features of childhood granulomatosis with polyangiitis (wegener's
30 granulomatosis). *Pediatr Rheumatol Online J* 12:18
31
32
33
34
35
36
37
38
39
40
41 5. Hattori M, Kurayama H, Koitabashi Y; Japanese Society for Pediatric Nephrology
42 (2001) Antineutrophil cytoplasmic autoantibody-associated glomerulonephritis in
43 children. *J Am Soc Nephrol* 7:1493-1500
44
45
46
47
48
49 6. Peco-Antic A, Bonaci-Nikolic B, Basta-Jovanovic G, Kostic M, Markovic-Lipkovski J,
50 Nikolic M, Spasojevic B (2006) Childhood microscopic polyangiitis associated with
51 MPO-ANCA. *Pediatr Nephrol* 1:46-53
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4 7. Schwartz GJ, Haycock GB, Edelmann CM, Jr., Spitzer A (1976) A simple estimate of
5
6 glomerular filtration rate in children derived from body length and plasma creatinine.
7
8 Pediatrics 2:259-263
9
- 10
11 8. Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K, Neumann I, Noel
12
13 LH, Pusey CD, Waldherr R, Bruijn JA, Bajema IM (2010) Histopathologic classification
14
15 of ANCA-associated glomerulonephritis. J Am Soc Nephrol 10:1628-1636
16
17
18
19
- 20 9. Ford SL, Polkinghorne KR, Longano A, Dowling J, Dayan S, Kerr PG, Holdsworth
21
22 SR, Kitching AR, Summers SA (2014) Histopathologic and clinical predictors of kidney
23
24 outcomes in ANCA-associated vasculitis. Am J Kidney Dis 2:227-235
25
26
27
- 28 10. Noone DG, Twilt M, Hayes WN, Thorner PS, Benseler S, Laxer RM, Parekh RS,
29
30 Hebert D (2014) The new histopathologic classification of ANCA-associated GN and its
31
32 association with renal outcomes in childhood. Clin J Am Soc Nephrol 10:1684-1691
33
34
35
- 36 11. Belostotsky VM, Shah V, Dillon MJ (2002) Clinical features in 17 paediatric patients
37
38 with Wegener granulomatosis. Pediatr Nephrol 9:754-761
39
40
- 41 12. Arulkumaran N, Jawad S, Smith SW, Harper L, Brogan P, Pusey CD, Salama AD
42
43 (2011) Long-term outcome of paediatric patients with ANCA vasculitis. Pediatr
44
45 Rheumatol Online J 9:12
46
47
- 48 13. Siomou E, Tramma D, Bowen C, Milford DV (2012) ANCA-associated
49
50 glomerulonephritis/systemic vasculitis in childhood: clinical features-outcome. Pediatr
51
52 Nephrol 10:1911-1920
53
54
55
56
57
58
59
60
61

- 1
2
3
4 14. Yu F, Huang JP, Zou WZ, Zhao MH (2006) The clinical features of anti-neutrophil
5
6 cytoplasmic antibody-associated systemic vasculitis in Chinese children. *Pediatr*
7
8 *Nephrol* 4:497-502
9
- 10
11 15. de Joode AA, Sanders JS, Stegeman CA (2013) Renal survival in proteinase 3 and
12
13 myeloperoxidase ANCA-associated systemic vasculitis. *Clin J Am Soc Nephrol*
14
15 10:1709-1717
16
17
18
19 16. Sinico RA, Di Toma L, Radice A (2013) Renal involvement in anti-neutrophil
20
21 cytoplasmic autoantibody associated vasculitis. *Autoimmun Rev* 4:477-48217. Krmar
22
23 RT, Kagebrand M, Hansson ME, Halling SE, Asling-Monemi K, Herthelius M, Holtback
24
25 U, Christensson M, Wernerson A, Bruchfeld A (2013) Renal-limited vasculitis in
26
27 children: a single-center retrospective long-term follow-up analysis. *Clin Nephrol* 5:388-
28
29 394
30
31
32
33
34 18. Akikusa JD, Schneider R, Harvey EA, Hebert D, Thorner PS, Laxer RM, Silverman
35
36 ED (2007) Clinical features and outcome of pediatric Wegener's granulomatosis.
37
38 *Arthritis Rheum* 5:837-844
39
40
41
42 19. Basu B, Mahapatra TK, Mondal N (2015) Favourable renal survival in paediatric
43
44 microscopic polyangiitis: efficacy of a novel treatment algorithm. *Nephrol Dial*
45
46 *Transplant* 30 Suppl 1:i113-118
47
48
49
50 20. Sacri AS, Chambaraud T, Ranchin B, Florkin B, See H, Decramer S, Flodrops H,
51
52 Ulinski T, Allain-Launay E, Boyer O, Dunand O, Fischbach M, Hachulla E, Pietrement
53
54 C, Le Pogamp P, Stephan JL, Belot A, Nivet H, Nobili F, Guillevin L, Quartier P,
55
56 Deschenes G, Salomon R, Essig M, Harambat J (2015) Clinical characteristics and
57
58
59
60
61
62
63
64
65

1
2
3
4 outcomes of childhood-onset ANCA-associated vasculitis: a French nationwide study.
5
6 Nephrol Dial Transplant 30 Suppl 1:i104-112
7
8

9
10 21. Valentini RP, Smoyer WE, Sedman AB, Kershaw DB, Gregory MJ, Bunchman TE
11 (1998) Outcome of antineutrophil cytoplasmic autoantibodies-positive
12 glomerulonephritis and vasculitis in children: a single-center experience. J Pediatr
13 2:325-328
14
15
16
17
18

19
20 22. Walsh M, Flossmann O, Berden A, Westman K, Hoglund P, Stegeman C, Jayne D;
21 European Vasculitis Study Group (2012) Risk factors for relapse of antineutrophil
22 cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2:542-548
23
24
25
26

27
28 23. Ellis EN, Wood EG, Berry P (1995) Spectrum of disease associated with anti-
29 neutrophil cytoplasmic autoantibodies in pediatric patients. J Pediatr 1:40-43
30
31
32

33
34 24. Day CJ, Howie AJ, Nightingale P, Shabir S, Adu D, Savage CO, Hewins P (2010)
35 Prediction of ESRD in pauci-immune necrotizing glomerulonephritis: quantitative
36 histomorphometric assessment and serum creatinine. Am J Kidney Dis 2:250-258
37
38
39

40
41 25. Bakkaloglu A, Ozen S, Baskin E, Besbas N, Gur-Guven A, Kasapcopur O,
42 Tinaztepe K (2001) The significance of antineutrophil cytoplasmic antibody in
43 microscopic polyangitis and classic polyarteritis nodosa. Arch Dis Child 5:427-430
44
45
46
47

48
49 26. Cabral DA, Uribe AG, Benseler S, O'Neil KM, Hashkes PJ, Higgins G, Zeft AS,
50 Lovell DJ, Kingsbury DJ, Stevens A, McCurdy D, Chira P, Abramson L, Arkachaisri T,
51 Campillo S, Eberhard A, Hersh AO, Huber AM, Kim S, Klein-Gitelman M, Levy DM, Li
52 SC, Mason T, Dewitt EM, Muscal E, Nassi L, Reiff A, Schikler K, Singer NG, Wahezi D,
53 Woodward A; ARChiVe (A Registry for Childhood Vasculitis: e-entry) Investigators
54
55
56
57
58
59
60
61

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Network (2009) Classification, presentation, and initial treatment of Wegener's granulomatosis in childhood. *Arthritis Rheum* 11:3413-3424

27. Khalighi MA, Wang S, Henriksen KJ, Bock M, Keswani M, Chang A, Meehan SM (2015) Pauci-immune glomerulonephritis in children: a clinicopathologic study of 21 patients. *Pediatr Nephrol* 6:953-959

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

LIST OF TABLES:

Table 1: Summary of Patient Characteristics at Presentation

BUN: blood urea nitrogen, IQR: interquartile range

Table 2: Renal Outcomes at Median Follow-up of 5.8 years

CKD: chronic kidney disease, eGFR: estimated glomerular filtration rate, ESRD: end-stage renal disease, Tx: transplantation

Table 3: Summary of Literature Reported on ANCA-Positive Glomerulonephritis

LIST OF FIGURES:

Figure 1: Systemic Symptoms at Presentation of Patients with ANCA-Positive Glomerulonephritis

Figure 2: Kaplan-Meier Curve Illustrating Relapse-Free Survival for Patients with First-Time Clinical or Serologic Relapse

<u>Gender [n(%)]</u>	
<u>Male</u>	9 (41)
<u>Female</u>	13 (59)
<u>Age (Median in years)</u>	
<u>Male</u>	13.7 (IQR 4.2)
<u>Female</u>	15.6 (IQR 3.6)
<u>Female</u>	11.9 (IQR 4.8)
<u>Serology [n(%)]</u>	
<u>c-ANCA/PR3</u>	9 (41)
<u>p-ANCA/MPO</u>	9 (41)
<u>c-ANCA</u>	0 (0)
<u>p-ANCA</u>	1 (4.5)
<u>PR3</u>	0 (0)
<u>MPO</u>	1 (4.5)
<u>Both</u>	1 (4.5)
<u>Other</u>	1 (4.5) (Initially negative, then seroconverted to p-ANCA)
<u>Median BUN</u>	
<u>(mg/dL)</u>	40.5 (IQR 52) ¹
<u>Median Creatinine</u>	
<u>(mg/dL)</u>	2.7 (IQR 5.4) ²
<u>% with Hematuria</u>	100%
<u>% with Proteinuria</u>	100%
<u>Median Protein:Creatinine</u>	
<u>(mg/mg)</u>	1.5 (IQR 4.1) ³
<u>Pathologic Findings on Biopsy [n(%)]⁴</u>	
<u>Focal</u>	0 (0)
<u>Crescentic</u>	10 (53)
<u>Mixed</u>	4 (21)
<u>Sclerotic</u>	5 (26)

Table 1: Summary of Patient Characteristics at Presentation

¹ 20 of 22 patients have BUN reported at presentation

² 21 of 22 patients have creatinine reported at presentation

³ 14 of 22 patients have Pr/Cr ratios reported at presentation

⁴ 2 biopsies at outside institutions not included in classification

Residual Renal function	Number of patients
CKD 1 (eGFR > 90 mL/min/1.73m²)	6
CKD 2 (eGFR 60-89 mL/min/1.73m²)	3
CKD 3 (eGFR 30-59 mL/min/1.73m²)	3
CKD 5/ESRD/Tx (eGFR <15 mL/min/1.73m² or dialysis)	7
Lost to follow-up	2
Deceased	1
TOTAL	22

Table 2: Renal Outcomes at Median Follow-up of 5.8 years

Table 3

	Ellis 1995 [23]	Valentini 1998 [21]	Bakkaloglu 2001 [25]	Hattori 2001 [5]	Belostotsky 2002 [11]	Peco- Antic 2006 [6]	Yu 2006 [14]	Akikusa 2007 [18]	Cabral 2009 [26]	Arulkumaran 2011 [12]	Siomou 2012 [13]	Krmar 2013 [17]	Noone 2014 [10]	Bohm 2014 [4]	Basu 2015 [19]	Khalighi 2015 [27]	Sacri 2015 [20]	
n=	5	7	10	31	17	7	20	25	65	8	13	6	40	56	11	21	66	
Length of Follow-Up (years) ⁵	---	2 ± 1	6 ⁶	3.75 ± 2.4	---	2.95 ± 1.9	1.0 ± 0.43	2.73 ²	---	19	3.2 ± 2.9	4.4	2.4 ²	---	1.74 ²	2.5 ⁶	5.2 ⁶	
Age at Presentation (years) ¹	11.5 ± 2.5	13.0 ± 0.9	12 ⁶	11.9 ± 2.9	6	12.0 ± 2.6	10.8 ± 2.8	14.5 ²	14.2 ²	11.5	13.2 ± 2.9	10.6	12 ²	11.7 ²	7.6 ²	14 ²	11.5 ⁶	
Gender	F (%)	4 (82)	5 (71)	6 (60)	27 (87)	13 (76)	6 (86)	18 (90)	20 (80)	41 (63.1)	6 (75)	10 (77)	5 (83)	28 (70)	38 (68)	6 (55)	15 (71)	55 (83)
	M (%)	1 (18)	2 (29)	4 (4)	4 (13)	4 (24)	1 (14)	2 (10)	5 (20)	24 (36.9)	2 (25)	11 (23)	1 (17)	12 (30)	18 (32)	5 (45)	6 (29)	11 (17)
Serology	MPO (%)	---	---	10 (100)	28 (90.3)	---	7 (100)	19 (95)	4 (16)	8 (12.3)	2 (25)	5 (38)	6 (100)	10 (25)	13 (26)	11 (100)	10 (48)	39 (59)
	PR3 (%)	---	---	0	3 (9.7)	---	0	1 (5)	15 (60)	44 (67.7)	4 (50)	7 (54)	0 (0)	18 (45)	34 (67)	0	7 (33)	22 (33)
	Other	2 (40)c- 2 (40)p- 1 unk	4 (57) c- 3 (43) p-	---	---	10 (59) c- 0 p-	---	---	Unstated 2 (8), ANCA negative 1 (4)	43 (66.2) c- 14 (21.5) p- 4 ANCA negative 1 PR3 & MPO positive	Neither 2 (25)	Neither 1 (8)	---	19 (47.5) p- 11 (27.5) c- ANCA negative 9 (22.5)	46 (82.7) ANCA positive	10 (91) p-	3 neg; 1 unk.	43 (65) c- 22 (33) p- 1 (2) both
Patients with Renal Involvement (%)	5 (100)	7 (100)	6 (60)	31 (100)	9 (53)	7 (100)	20 (100)	22 (88)	49 (75.4)	5 (63)	13 (100)	6 (100)	40 (100)	23 (82)	11 (100)	21 (100)	58 (88)	
Dialysis at Presentation (%)	---	2 (29)	---	7 (23)	1 (6)	2 (29)	5 (25)	5 (20)	---	1 (12.5)	1 (8)	1 (17)	12 (30)	---	9 (82)	---	9 (14)	
Development of ESRD (%)	---	1 (14)	4 (40)	9 (29)	1 (6)	2 (29)	10 (50)	3 (12)	---	1 (12.5)	3 (23)	0	14 (35)	---	0	7 (37)	22 (34)	

Table 3: Summary of Literature Reported on Pediatric ANCA-Associated Vasculitis

¹ Reported as mean unless otherwise noted² Reported as median

--- = not available

Figure 1




Figure 1: Systemic Symptoms at Presentation of Patients with ANCA-Positive Glomerulonephritis

Figure 2




Figure 2: Kaplan-Meier Curve Illustrating Relapse-Free Survival For Patients with First-Time Clinical or Serologic Relapse




Figure 1: Systemic Symptoms at Presentation of Patients with ANCA-Positive Glomerulonephritis




Figure 2: Kaplan-Meier Curve Illustrating Relapse-Free Survival For Patients with First-Time Clinical or Serologic Relapse

<u>Gender [n(%)]</u>	
Male	9 (41)
Female	13 (59)
<u>Age (Median in years)</u>	
Male	15.6 (IQR 3.6)
Female	11.9 (IQR 4.8)
<u>Serology [n(%)]</u>	
c-ANCA/PR3	9 (41)
p-ANCA/MPO	9 (41)
c-ANCA	0 (0)
p-ANCA	1 (4.5)
PR3	0 (0)
MPO	1 (4.5)
Both	1 (4.5)
Other	1 (4.5) (Initially negative, then seroconverted to p-ANCA)
<u>Median BUN (mg/dL)</u>	
	40.5 (IQR 52) ¹
<u>Median Creatinine (mg/dL)</u>	
	2.7 (IQR 5.4) ²
<u>% with Hematuria</u>	100%
<u>% with Proteinuria</u>	100%
<u>Median Protein:Creatinine (mg/mg)</u>	
	1.5 (IQR 4.1) ³
<u>Pathologic Findings on Biopsy [n(%)]⁴</u>	
Focal	0 (0)
Crescentic	10 (53)
Mixed	4 (21)
Sclerotic	5 (26)

Table 1: Summary of Patient Characteristics at Presentation

¹ 20 of 22 patients have BUN reported at presentation

² 21 of 22 patients have creatinine reported at presentation

³ 14 of 22 patients have Pr/Cr ratios reported at presentation

⁴ 2 biopsies at outside institutions not included in classification

Residual Renal function	Number of patients
CKD 1 (eGFR > 90 mL/min/1.73m²)	6
CKD 2 (eGFR 60-89 mL/min/1.73m²)	3
CKD 3 (eGFR 30-59 mL/min/1.73m²)	3
CKD 5/ESRD/Tx (eGFR <15 mL/min/1.73m² or dialysis)	7
Lost to follow-up	2
Deceased	1
TOTAL	22

Table 2: Renal Outcomes at Median Follow-up of 5.8 years

	Ellis 1995 [23]	Valentini 1998 [21]	Bakkaloglu 2001 [25]	Hattori 2001 [5]	Belostotsky 2002 [11]	Peco- Antic 2006 [6]	Yu 2006 [14]	Akikusa 2007 [18]	Cabral 2009 [26]	Arulkumaran 2011 [12]	Siomou 2012 [13]	Krmar 2013 [17]	Noone 2014 [10]	Bohm 2014 [4]	Basu 2015 [19]	Khalighi 2015 [27]	Sacri 2015 [20]	
n=	5	7	10	31	17	7	20	25	65	8	13	6	40	56	11	21	66	
Length of Follow-Up (years) ⁵	---	2 ± 1	6 ⁶	3.75± 2.4	---	2.95 ± 1.9	1.0 ± 0.43	2.73 ²	---	19	3.2 ± 2.9	4.4	2.4 ²	---	1.74 ²	2.5 ⁶	5.2 ⁶	
Age at Presentation (years) ¹	11.5 ± 2.5	13.0 ± 0.9	12 ⁶	11.9 ± 2.9	6	12.0 ± 2.6	10.8 ± 2.8	14.5 ²	14.2 ²	11.5	13.2 ± 2.9	10.6	12 ²	11.7 ²	7.6 ²	14 ²	11.5 ⁶	
Gender	F (%)	4 (82)	5 (71)	6 (60)	27 (87)	13 (76)	6 (86)	18 (90)	20 (80)	41 (63.1)	6 (75)	10 (77)	5 (83)	28 (70)	38 (68)	6 (55)	15 (71)	55 (83)
	M (%)	1 (18)	2 (29)	4 (4)	4 (13)	4 (24)	1 (14)	2 (10)	5 (20)	24 (36.9)	2 (25)	11 (23)	1 (17)	12 (30)	18 (32)	5 (45)	6 (29)	11 (17)
Serology	MPO (%)	---	---	10 (100)	28 (90.3)	---	7 (100)	19 (95)	4 (16)	8 (12.3)	2 (25)	5 (38)	6 (100)	10 (25)	13 (26)	11 (100)	10 (48)	39 (59)
	PR3 (%)	---	---	0	3 (9.7)	---	0	1 (5)	15 (60)	44 (67.7)	4 (50)	7 (54)	0 (0)	18 (45)	34 (67)	0	7 (33)	22 (33)
	Other	2 (40)c- 2 (40)p- 1 unk	4 (57) c- 3 (43) p-	---	---	10 (59) c- 0 p-	---	---	Unstated 2 (8), ANCA negative 1 (4)	43 (66.2) c- 14 (21.5) p- 4 ANCA negative 1 PR3 & MPO positive	Neither 2 (25)	Neither 1 (8)	---	19 (47.5) p- 11 (27.5) c- ANCA negative 9 (22.5)	46 (82.7) ANCA positive	10 (91) p-	3 neg; 1 unk.	43 (65) c- 22 (33) p- 1 (2) both
Patients with Renal Involvement (%)	5 (100)	7 (100)	6 (60)	31 (100)	9 (53)	7 (100)	20 (100)	22 (88)	49 (75.4)	5 (63)	13 (100)	6 (100)	40 (100)	23 (82)	11 (100)	21 (100)	58 (88)	
Dialysis at Presentation (%)	---	2 (29)	---	7 (23)	1 (6)	2 (29)	5 (25)	5 (20)	---	1 (12.5)	1 (8)	1 (17)	12 (30)	---	9 (82)	---	9 (14)	
Development of ESRD (%)	---	1 (14)	4 (40)	9 (29)	1 (6)	2 (29)	10 (50)	3 (12)	---	1 (12.5)	3 (23)	0	14 (35)	---	0	7 (37)	22 (34)	

Table 3: Summary of Literature Reported on Pediatric ANCA-Associated Vasculitis

¹ Reported as mean unless otherwise noted

² Reported as median

--- = not available